Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/26/25 | Altimmune (ALT) | Pemvidutide for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
6/24/25 | MindRank | MDR-001 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
6/23/25 | Eli Lilly (LLY) | Mazdutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
6/23/25 | COMPASS Pathways (CMPS) | COMP360 for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
6/23/25 | Cidara Therapeutics (CDTX) | CD388 for Influenza (including vaccines) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |